Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8135875rdf:typepubmed:Citationlld:pubmed
pubmed-article:8135875lifeskim:mentionsumls-concept:C0006772lld:lifeskim
pubmed-article:8135875lifeskim:mentionsumls-concept:C0012373lld:lifeskim
pubmed-article:8135875lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:8135875lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:8135875pubmed:issue1lld:pubmed
pubmed-article:8135875pubmed:dateCreated1994-4-18lld:pubmed
pubmed-article:8135875pubmed:abstractTextA series of newly synthesized 1,5-benzothiazepines derived from diltiazem (CAS 42399-41-7) were tested for calmodulin antagonistic activities using Ca(2+)-calmodulin stimulated phosphodiesterase (PDE). Some compounds possessing the benzoyloxy moieties at position 4 of 1,5-benzothiazepine ring of diltiazem showed a dose-dependent inhibitory action with the potencies comparable to that of a calmodulin antagonist, N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide (W-7). In contrast, diltiazem did not exert the inhibitory action at the same concentrations. Further, radioligand binding experiment, using a radiolabeled 1,5-benzothiazepine, showed that these compounds bound to Ca(2+)-calmodulin complex, but not to calmodulin in the presence of EGTA, suggesting that these 1,5-benzothiazepines are new calmodulin antagonists. Some of these compounds inhibited [3H]diltiazem binding to Ca antagonist binding sites in cell membranes of rat cerebral cortex but with a less potent affinities than diltiazem, suggesting that there was no correlation between their anti-calmodulin effect and the binding affinity to Ca antagonist binding sites. In conclusion, new 1,5-benzothiazepines have been demonstrated to have an anti-calmodulin action. These compounds may possess a pharmacological activity based on their anti-calmodulin action in addition to their interaction with Ca channel.lld:pubmed
pubmed-article:8135875pubmed:languageenglld:pubmed
pubmed-article:8135875pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:citationSubsetIMlld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135875pubmed:statusMEDLINElld:pubmed
pubmed-article:8135875pubmed:monthJanlld:pubmed
pubmed-article:8135875pubmed:issn0004-4172lld:pubmed
pubmed-article:8135875pubmed:authorpubmed-author:SuzukiTTlld:pubmed
pubmed-article:8135875pubmed:authorpubmed-author:OhashiMMlld:pubmed
pubmed-article:8135875pubmed:authorpubmed-author:TakaitiOOlld:pubmed
pubmed-article:8135875pubmed:authorpubmed-author:HarigayaSSlld:pubmed
pubmed-article:8135875pubmed:issnTypePrintlld:pubmed
pubmed-article:8135875pubmed:volume44lld:pubmed
pubmed-article:8135875pubmed:ownerNLMlld:pubmed
pubmed-article:8135875pubmed:authorsCompleteYlld:pubmed
pubmed-article:8135875pubmed:pagination3-6lld:pubmed
pubmed-article:8135875pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:meshHeadingpubmed-meshheading:8135875-...lld:pubmed
pubmed-article:8135875pubmed:year1994lld:pubmed
pubmed-article:8135875pubmed:articleTitleCalmodulin antagonistic action of new 1,5-benzothiazepines derived from diltiazem.lld:pubmed
pubmed-article:8135875pubmed:affiliationBiological Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan.lld:pubmed
pubmed-article:8135875pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8135875pubmed:publicationTypeIn Vitrolld:pubmed